Andersen G S
Acta Med Scand. 1985;218(2):165-72. doi: 10.1111/j.0954-6820.1985.tb08843.x.
The antihypertensive effect and patient tolerability during 12 weeks' treatment with atenolol and bendroflumethiazide were evaluated in an open, randomized, between-patient trial. Out of a total of 162 patients, aged 50-75 years, with previously untreated hypertension, 151 completed the trial. They were randomly allocated to two groups. Forty-nine patients, aged 50-64 years (middle-aged), and 23, aged 65-75 years (elderly), were treated with atenolol. Forty middle-aged and 39 elderly were treated with bendroflumethiazide. Significant reductions in blood pressure (BP) were observed during treatment with each drug (p less than 0.001). The change in diastolic BP in middle-aged patients was significant in favour of atenolol (p less than 0.01), but otherwise no difference was found between the two drugs. Uric acid increased during treatment with both drugs (p less than 0.001). Serum potassium decreased during bendroflumethiazide treatment (p less than 0.001). Subjective side-effects of both drugs were few and expected. The results of this study indicate that atenolol and bendroflumethiazide are equally effective in reducing BP in patients aged 50-75 years.
在一项开放性、随机、患者间对照试验中，评估了阿替洛尔和苄氟噻嗪治疗12周期间的降压效果及患者耐受性。共有162例年龄在50至75岁之间、此前未经治疗的高血压患者参与试验，其中151例完成了试验。他们被随机分为两组。49例年龄在50至64岁（中年）的患者和23例年龄在65至75岁（老年）的患者接受阿替洛尔治疗。40例中年患者和39例老年患者接受苄氟噻嗪治疗。使用每种药物治疗期间均观察到血压（BP）显著降低（p<0.001）。中年患者舒张压的变化对阿替洛尔有利，差异有统计学意义（p<0.01），但除此之外，两种药物之间未发现差异。两种药物治疗期间尿酸均升高（p<0.001）。苄氟噻嗪治疗期间血清钾降低（p<0.001）。两种药物的主观副作用均较少且在预期范围内。本研究结果表明，阿替洛尔和苄氟噻嗪在降低50至75岁患者血压方面同样有效。
